Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review

Folia Neuropathologica

Volumn 49, Issue 2, 2011, Pages 94-102

  Zawrocki, Antoni ^a   Izycka Świeszewska, Ewa ^a   Papierz, Wielisław ^b   Liberski, Paweł P ^b   Zakrzewski, Krzysztof ^c   Biernat, Wojciech ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Cyclin D1; Ependymoma; Immunohistochemistry; Ki 67; Mitotic index; Olig2; Prognosis

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; EPENDYMOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; INTRACRANIAL TUMOR; MALE; MITOSIS INDEX; MORPHOLOGY; NECROSIS; OVERALL SURVIVAL; PRESCHOOL CHILD; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SPINAL CORD TUMOR; SURVIVAL RATE;

EID: 79960469029     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Agaoglu FY, Ayan I, Dizdar Y, Kebudi R, Gorgun O, Darendeliler E. Ependymal tumors in childhood. Pediatr Blood Cancer 2005; 45: 298-303. (Pubitemid 41077163)
2. Bennetto L, Foreman N, Harding B, Hayward R, Ironside J, Love S, Ellison D. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol 1998; 24: 434-440. (Pubitemid 29002274)
3. Bouffet E, Perilongo G, Canete A, Massimino M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998; 30: 319-329.
4. Figarella-Branger D, Civatte M, Bouvier-Labit C, Gouvernet J, Gambarelli D, Gentet JC, Lena G, Choux M, Pellissier JF. Prognostic factors in intracranial ependymomas in children. J Neurosurg 2000; 93: 605-613. (Pubitemid 32799294)
5. Gal R, Rath-Wolfson L, Rosenblatt Y, Halpern M, Schwartz A, Koren R. An improved technique for mitosis counting. Int J Surg Pathol 2005; 13: 161-165. (Pubitemid 40617544)
6. Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, Connelly M, Wetmore C, Curran T, Elenius K, Ellison DW. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002; 8: 3054-3064. (Pubitemid 35155014)
7. Gilles FH, Sobel EL, Tavare CJ, Leviton A, Hedley-Whyte ET. Age-related changes in diagnoses, histological features, and survival in children with brain tumors: 1930-1979. The Childhood Brain Tumor Consortium. Neurosurgery 1995; 37: 1056-1068.
8. Grzybicki DM, Liu Y, Moore SA, Brown HG, Silverman JF, D'Amico F, Raab SS. Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer 2001; 92: 2720-2726. (Pubitemid 33049457)
9. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, Krush AJ, Berk T, Cohen Z, Tetu B, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332: 839-847.
10. Ho DM, Hsu CY, Wong TT, Chiang H. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma. J Neurooncol 2001; 54: 77-85. (Pubitemid 33089263)
11. Ishizawa K, Komori T, Shimada S, Hirose T. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. Clin Neuropathol 2008; 27: 118-128. (Pubitemid 351678187)
12. Jaing TH, Wang HS, Tsay PK, Tseng CK, Jung SM, Lin KL, Lui TN. Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas. J Neurooncol 2004; 68: 255-261.
13. Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 2004; 100: 1230-1237. (Pubitemid 38325952)
14. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol 2002; 58: 255-270. (Pubitemid 34830636)
15. Korshunov A, Sycheva R, Timirgaz V, Golanov A. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases. J Neurooncol 1999; 45: 219-227. (Pubitemid 30315739)
16. Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ, Avezaat CJ, Kros JM. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer 2006; 106: 388-395. (Pubitemid 43100449)
17. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, Anderson DJ, Stiles CD, Rowitch DH. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007; 53: 503-517. (Pubitemid 46216748)
18. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. (Pubitemid 47103521)
19. Mansur DB, Perry A, Rajaram V, Michalski JM, Park TS, Leonard JR, Luchtman-Jones L, Rich KM, Grigsby PW, Lockett MA, Wahab SH, Simpson JR. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 2005; 61: 387-391. (Pubitemid 40164431)
20. Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY, Poirier J, Zalc B, Hoang-Xuan K. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 2001; 358: 298-300. (Pubitemid 32738972)
21. McLaughlin MP, Marcus RB Jr, Buatti JM, McCollough WM, Mickle JP, Kedar A, Maria BL, Million RR. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 1998; 40: 845-850. (Pubitemid 28150802)
22. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, Lichter P. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006; 12: 2070-2079.
23. Monoranu CM, Huang B, Zangen IL, Rutkowski S, Vince GH, Gerber NU, Puppe B, Roggendorf W. Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas. Cancer Genet Cytogenet 2008; 182: 18-26. (Pubitemid 351323960)
24. Ohnishi A, Sawa H, Tsuda M, Sawamura Y, Itoh T, Iwasaki Y, Nagashima K. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas. J. Neuropathol. Exp Neurol 2003; 62: 1052-1059. (Pubitemid 37229534)
25. Perilongo G, Massimino M, Sotti G, Belfontali T, Masiero L, Rigobello L, Garr? L, Carli M, Lombardi F, Solero C, Sainati L, Canale V, del Prever AB, Giangaspero F, Andreussi L, Mazza C, Madon E. Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neuro-oncology Group Med Pediatr Oncol 1997; 29: 79-85.
26. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173. (Pubitemid 43357943)
27. Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL, Janosky J, Deutsch M. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 1995; 37: 655-666.
28. Prayson RA. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases. Am J Clin Pathol 1998; 110: 629-634. (Pubitemid 28491968)
29. Prayson RA. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann Diagn Pathol 1999; 3: 11-18.
30. Preusser M, Heinzl H, Gelpi E, Höftberger R, Fischer I, Pipp I, Milenkovic I, Wöhrer A, Popovici F, Wolfsberger S, Hainfellner JA. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 2008; 53: 39-47.
31. Preusser M, Wolfsberger S, Czech T, Slavc I, Budka H, Hainfellner JA. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol 2005; 124: 543-549. (Pubitemid 41395635)
32. Preusser M, Wolfsberger S, Haberler C, Breitschopf H, Czech T, Slavc I, Harris AL, Acker T, Budka H, Hainfellner JA. Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol 2005; 109: 211-216. (Pubitemid 40468391)
33. ther FJ, Löhler J, Herms J, Hugo HH, Schindler C, Leithäuser F, Melzner I, Möller P, Scheil S. Low incidence of SV40-like sequences in ependymal tumours. J Pathol 2001; 195: 580-585.
34. Rhee W, Ray S, Yokoo H, Hoane ME, Lee CC, Mikheev AM, Horner PJ, Rostomily RC. Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia 2009; 57: 510-523.
35. Ridley L, Rahman R, Brundler MA, Ellison D, Lowe J, Robson K, Prebble E, Luckett I, Gilbertson RJ, Parkes S, Rand V, Coyle B, Grundy RG; Children's Cancer and Leukaemia Group Biological Studies Committee. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol 2008; 10: 675-689.
36. Ritter AM, Hess KR, McLendon RE, Langford LA. Ependymomas: MIB-1 proliferation index and survival. J Neurooncol 1998; 40: 51-57. (Pubitemid 28548372)
37. Sala F, Talacchi A, Mazza C, Prisco R, Ghimenton C, Bricolo A. Prognostic factors in childhood intracranial ependymomas: the role of age and tumor location. Pediatr Neurosurg 1998; 28: 135-142. (Pubitemid 28385584)
38. Schiffer D, Chi? A, Giordana MT, Migheli A, Palma L, Pollo B, Soffietti R, Tribolo A. Histologic prognostic factors in ependymoma. Childs Nerv Syst 1991; 7: 177-182.
39. Schwartz TH, Kim S, Glick RS, Bagiella E, Balmaceda C, Fetell MR, Stein BM, Sisti MB, Bruce JN. Supratentorial ependymomas in adult patients. Neurosurgery 1999; 44: 721-731. (Pubitemid 29153564)
40. Tabori U, Ma J, Carter M, Zielenska M, Rutka J, Bouffet E, Bartels U, Malkin D, Hawkins C. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol 2006; 24: 1522-1528. (Pubitemid 46638773)
41. Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ. The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol 2008; 21: 165-177. (Pubitemid 351172168)
42. van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, Sainte-Rose C, Zerah M, Thorne J, Renier D. Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J. Neurosurg 2002; 97: 827-835. (Pubitemid 35222404)
43. Wolfsberger S, Fischer I, Höftberger R, Birner P, Slavc I, Dieckmann K, Czech T, Budka H, Hainfellner J. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol 2004; 28: 914-920. (Pubitemid 38856848)
44. Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, Aradi J, Lanotte M, Tong JH, Chen GQ, Ségal-Bendirdjian E. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci 2006; 119: 2797-2806. (Pubitemid 44184016)
45. Zamecnik J, Snuderl M, Eckschlager T, Chanova M, Hladikova M, Tichy M, Kodet R. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol 2003; 16: 980-991. (Pubitemid 37280813)